肿瘤相关基因在肝细胞癌及癌旁正常肝组织中表达

Expression of tumor related genes in hepatocellular carcinomas and adjacent noncancerous liver tissues and their clinical significances

目的 探讨肿瘤相关基因dek、cyclinD1、胰岛素样生长因子Ⅱ (IGF Ⅱ )、GPC3、核糖体蛋白 0 (rpP0 )mRNA在肝细胞癌 (HCC)组织中及癌旁正常肝组织中的表达及其临床意义。方法 应用RT PCR方法检测 32例HCC组织及相应癌旁正常肝组织中dek、cyclinD1、IGF Ⅱ、GPC3和rpP0mRNA的表达情况。 结果 dek、cyclinD1、IGF Ⅱ、GPC3、rpP0mRNA在癌组织中阳性表达率为 78 1%、87 5 %、87 5 %、75 0 %和 81 3% ,在癌旁正常肝组织中阳性表达率为 15 6 %、4 0 6 %、 37 5 %、2 1 9%和 31 3% ,差异有显著性 (P <0 0 5 )。dek、cyclinD1、IGF Ⅱ、GPC3、rpP0mRNA在高分化HCC组织中阳性率为89 0 %、6 6 7%、6 6 7%、6 6 7%和 77 8% ,在低分化HCC组织中阳性率为 73 9%、95 7%、95 7%、95 7%和 82 6 % ,差异无显著性 (P >0 0 5 )。在AFP阴性的HCC中其阳性率分别 90 0 %、80 0 %、90 0 %、90 0 %和 90 0 % ,而AFP阳性的HCC这些基因mRNA的阳性率为 72 7%、86 3%、77 3%、90 9%和 6 8 2 % ,差异无显著性意义 (P >0 0 5 )。结论 dek、cyclinD1、IGF Ⅱ、GPC3、rpP0mRNA在HCC组织中呈高表达状态 ,即使是AFP阴性的HCC也呈高表达 ,因此它们可以作为诊断HCC的基因标志 ,而且联合应用时意义更大。

Purpose To investigate the expression of dek, cyclin D1(CYD1), IGF-Ⅱ, GPC3, rpP0 mRNA in hepatocellular carcinomas (HCC) and adjacent noncancerous liver tissues, and their clinical significance. Methods The expression of mRNAs of dek, CYD1, IGF-Ⅱ, GPC3 and rpP0 mRNA was detected by RT-PCR in 32 HCC tissues and adjacent noncancerous liver tissues. Results The percentages of the over-expression of mRNAs of dek, CYD1, IGF-Ⅱ, GPC3, rpP0 mRNA in HCC and adjacent noncancerous liver tissues were 78.1%, 87.5%, 87.5%, 75.0%, 81.3% and 15.6%, 40.6%, 37.5%, 21.9%, and 31.3% respectively (P<0.05). The percentages of positive expression of mRNAs of dek, CYD1, IGF-Ⅱ, GPC3, rpP0 in well-differentiated and poor-differentiated HCC were 89.0%, 66.7%, 66.7%, 66.7%, 77.8% and 73.9%, 95.7%, 95.7%, 95.7%, and 82.6% respectively (P>0.05). The percentages of the expression of these genes in HCCs with AFP negative and positive were 90.0%, 80.0%, 90.0%, 90.0%, 90.0% and 72.7%, 86.3%, 77.3%, 90.9%,and 68.2% respectively (P>0.05). Conclusions The over-expression of dek, CYD1, IGF-Ⅱ, GPC3, rpP0 mRNA are involved in carcinogenesis and progression of HCC. They may also be used as markers in diagnosis of HCC, especially in AFP-negative HCC.